on Artcline GmbH
ARTCLINE Forms Scientific Advisory Board to Enhance Sepsis Treatment
Artcline GmbH has announced the establishment of a Scientific Advisory Board, bringing together renowned experts in nephrology, intensive care, and transfusion medicine. This strategic move aims to advance the development of ARTICE®, an innovative immune cell therapy targeting septic shock and immune paralysis.
Members of the advisory board come from leading medical institutions in Germany and bring diverse expertise in immunochemistry, organ dysfunction, and coagulation disorders. Their involvement underscores the significance of ARTICE® in addressing immune failure due to sepsis, a pressing healthcare challenge.
The ReActIF-ICE study is currently underway, assessing ARTICE® therapy across 20 intensive care units in Germany with plans to recruit 140 patients by the end of 2025. ARTCLINE is also preparing for market launch to provide new treatment options for sepsis.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Artcline GmbH news